ValuentumAd

Official PayPal Seal














Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Latest Valuentum Commentary

May 3, 2016
Dividend Increases/Decreases for the Week Ending April 29
Let's take a look at companies raising/lowering their dividends this week.
May 3, 2016
A Letter from the President
“We’re Valuentum, not value – and that’s all the difference in the world.” – Brian Nelson, CFA
May 2, 2016
Gilead: What's Your Long Term Thesis?
Image Source: Gilead. We’re starting to see some even bigger risks at Gilead – long-term ones.
Apr 29, 2016
Gilead Disappoints, Harvoni Sales Drop 16%
Image Source: Gilead. In January 2016, we had removed Gilead from the Best Ideas Newsletter portfolio, and we added steady-eddy dividend growth giant Johnson & Johnson in its place. We were starting to think we might have made a mistake … until today.
Apr 21, 2016
The Market – On Its Head
Let’s discuss what’s been working and what’s not been working in today’s market.
Mar 23, 2016
What Gilead’s Patent Miscue Means for Shareholders
Image Source: Gilead. Not much…right now, but we’re sleeping better at night not including shares in the newsletter portfolios.
Mar 14, 2016
The Corporate Buyback Conundrum
The broader risks to the market remain, and the biggest buyer of stock is not who you think. Are corporations the ones holding this market together?
Feb 22, 2016
Key Treatment Momentum Drives Big Pharma
Let’s take a look at the recent results of some of the biggest names in Big Pharma.
Feb 12, 2016
Your Hard-Earned Money
Valuentum is releasing its February Best Ideas Newsletter early, February 12, in light of Presidents’ Day weekend.
Feb 2, 2016
Early Read: Gilead Guides Revenue to Decline in 2016, Below Consensus
The growth spurt may be over, and we’re most worried about the back half of this decade.


Latest Press Releases



The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.